p-Aminophenylmercuric acetate is an organomercuric matrix metalloproteinase (MMP) activator. p-Aminophenylmercuric acetate participates in the activation and inhibition of MMP-8 by attacking protein sulfhydryl groups or inducing cysteine conversion reactions. p-Aminophenylmercuric acetate promotes beta-cellulose precursor (pro-BTC) shedding. p-Aminophenylmercuric acetate affects the binding of opioid receptors to their agonists and antagonists.

Physicochemical Properties

Molecular Formula	C8H9HGNO2
Molecular Weight	351.75
Exact Mass	353.034
CAS #	6283-24-5
PubChem CID	16682983
Appearance	White to yellow solid powder
Melting Point	163-165 °C(lit.)
LogP	1.035
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	3
Heavy Atom Count	12
Complexity	155
Defined Atom Stereocenter Count	0
InChi Key	RXSUFCOOZSGWSW-UHFFFAOYSA-M
InChi Code	InChI=1S/C6H6N.C2H4O2.Hg/c7-6-4-2-1-3-5-6;1-2(3)4;/h2-5H,7H2;1H3,(H,3,4);/q;;+1/p-1
Chemical Name	acetyloxy-(4-aminophenyl)mercury
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro

Rat brain homogenates treated with p-Aminophenylmercuric acetate (APMA) (0-30 µM; 20 min) exhibit a decrease in the quantity of dihydromorphine binding sites and an increase in agonist sensitivity to sodium binding inhibition [2]. Matrix metalloproteinases 2 and 9 are activated by 0.5 mM; 30 min; p-Aminophenylmercuric acetate [3].

References

[1]. ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx. Journal of Biological Chemistry, 2005, 280(3): 1826-1837. [2]. Differential effects of protein-modifying reagents on receptor binding of opiate agonists and antagonists. Molecular Pharmacology, 1975, 11(3): 340-351. [3]. Inhibition of the activities of matrix metalloproteinases 2, 8, and 9 by chlorhexidine. Clinical Diagnostic Laboratory Immunology, 1999, 6(3): 437-439.

Solubility Data

Solubility (In Vitro)

DMSO: 125 mg/mL (355.37 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.08 mg/mL (5.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.8429 mL	14.2146 mL	28.4293 mL
	5 mM	0.5686 mL	2.8429 mL	5.6859 mL
	10 mM	0.2843 mL	1.4215 mL	2.8429 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.